Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.79 |
| ▸ | MAPT | P10636 | 1/20 | 0.79 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | SORD | Q00796 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzisothiazole-3-Yl-Piperazine SCHEMBL250876 | 0.90 | KDM4E (0.97) | KDM4EMAPTHTR1ADRD2HTR2A | |
| Benzisothiazole-3-Yl-Piperazine SCHEMBL29432928 | 0.90 | KDM4E (0.97) | KDM4EMAPTHTR1ADRD2HTR2A | |
| Benzisothiazole-3-Yl-Piperazine SCHEMBL7996950 | 0.89 | KDM4E (1.00) | KDM4EMAPTHTR1ADRD2HTR2A | |
| Benzisothiazole-3-Yl-Piperazine SCHEMBL30204416 | 0.89 | KDM4E (1.00) | KDM4EMAPTHTR1ADRD2HTR2A | |
| Benzisothiazole-3-Yl-Piperazine SCHEMBL9207008 | 0.89 | KDM4E (0.94) | KDM4EMAPTHTR1ADRD2HTR2A | |
| Benzisothiazole-3-Yl-Piperazine SCHEMBL9208072 | 0.89 | KDM4E (1.00) | KDM4EMAPTHTR1ADRD2HTR2A | |
| Benzisothiazole-3-Yl-Piperazine SCHEMBL1737330 | 0.89 | KDM4E (1.00) | KDM4EMAPTHTR1ADRD2HTR2A | |
| Benzisothiazole-3-Yl-Piperazine SCHEMBL19733087 | 0.89 | KDM4E (0.94) | KDM4EMAPTHTR1ADRD2HTR2A | |
| SCHEMBL9722339 | 0.86 | KDM4E (0.88) | KDM4EMAPTHTR1ADRD2HTR2A | |
| Benzisothiazole-3-Yl-Piperazine SCHEMBL4685549 | 0.85 | KDM4E (0.81) | KDM4EMAPTHTR1ADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029700-A1 | 1-(2-ARYL-2-OXOETHYL)-3-PHENYL-1, 4-DIAZASPIRO [4.5]DEC-3-EN-2-ONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-02-04 | — | — | US | disclosed |
| US-20090227629-A1 | COMPOUNDS HAVING ACTIVITY AT THE GLYCINE TRANSPORTER GLYT1 AND USES THEREOF | GLAXO GROUP LIMITED | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029700-A1 | 1-(2-ARYL-2-OXOETHYL)-3-PHENYL-1, 4-DIAZASPIRO [4.5]DEC-3-EN-2-ONE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORTER INHIBITORS | SLC1A1, SLC1A5, SLC6A5 | KDM4E 2618/4885MAPT 4445/4885HTR1A 389/4885 |
| US-20090227629-A1 | COMPOUNDS HAVING ACTIVITY AT THE GLYCINE TRANSPORTER GLYT1 AND USES THEREOF | SLC18A2, SLC6A3, SLC6A2 | KDM4E 3681/4885MAPT 141/4885HTR1A 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.